Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 13.00 | 2,272 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 12.50 | 13.50 | 13.00 | 13.00 | 13.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Noncomml Resh Organizations | 644k | -2.04M | -0.0208 | -6.25 | 12.73M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:34:07 | O | 2,262 | 13.04 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/10/2024 | 07:00 | UK RNS | OptiBiotix Health PLC Requisition update |
| 25/10/2024 | 15:29 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
| 24/10/2024 | 06:00 | UK RNS | OptiBiotix Health PLC Total Voting Rights |
| 23/10/2024 | 14:54 | ALNC |  IN BRIEF: OptiBiotix Health finance director to step down in November |
| 23/10/2024 | 06:00 | UK RNS | OptiBiotix Health PLC Directorate Change |
| 18/10/2024 | 18:44 | ALNC | TRADING UPDATES: LMS Capital NAV falls; Cloudcoco sells unit |
| 18/10/2024 | 06:00 | UK RNS | OptiBiotix Health PLC Response to Publication of Circular by ProBiotix |
| 10/10/2024 | 06:00 | UK RNS | OptiBiotix Health PLC SlimBiome study update |
| 27/9/2024 | 12:56 | ALNC | EARNINGS: Kendrick Resources loss narrows; Emmerson CFO to depart |
| 27/9/2024 | 06:00 | UK RNS | OptiBiotix Health PLC Half-year Report |
Optibiotix Health (OPTI) Share Charts1 Year Optibiotix Health Chart |
|
1 Month Optibiotix Health Chart |
Intraday Optibiotix Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/11/2024 | 14:08 | OptiBiotix Health PLC - | 18,830 |
| 14/11/2024 | 16:51 | OptiBiotix Health (Facts NOT Fiction) | 5,390 |
| 12/11/2024 | 19:14 | OptiBiotix - The uncensored thread | 67,549 |
| 10/11/2024 | 12:52 | OPTI - Optibiotix Plc - The balanced Thread | 45 |
| 06/11/2024 | 11:39 | Optibiotix. The Company that always promises but never delivers. | 6 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:34:08 | 13.04 | 2,262 | 294.96 | O |
| 08:00:03 | 12.50 | 10 | 1.25 | O |
| 2024-11-20 15:08:17 | 12.67 | 3,714 | 470.38 | O |
| 2024-11-20 13:30:08 | 13.02 | 10,000 | 1,302.00 | O |
| 2024-11-20 13:30:01 | 13.00 | 20,000 | 2,600.00 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Optibiotix Health Daily Update Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 13p.Optibiotix Health currently has 97,943,161 shares in issue. The market capitalisation of Optibiotix Health is £12,732,611. Optibiotix Health has a price to earnings ratio (PE ratio) of -6.25. This morning OPTI shares opened at 13p |
Posted at 30/10/2024 07:43 by putinaire The neck of the knuts to complain about share price fallingWould they like to open up the PBX share register and show who the sellers were? |
Posted at 26/10/2024 18:44 by putinaire 2017OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans to launch products containing its cholesterol reducing strain (LPLDL®) at the Vitafoods Europe Trade Show ("Vitafoods") in Geneva on the 9-11 May 2017. The trade show provides opportunities to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. The event is viewed as one of the world's leading trade fairs for the food and drinks industry ............... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain in Europe with a view to maximising the financial return for both parties. .............. OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL® capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherhe ............... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year supply agreement with Galenicum Special Ingredients, S.L ("Galenicum") to commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL®. The agreement grants Galenicum a non-exclusive license to commercialise Cardiocare™, a nutritional supplement containing OptiBiotix's LPLDL® in Spain, Chile, Peru and the Middle East with the aim of maximising the financial return for both parties. .............. 2018 OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a production and commercialisation agreement with Fine Foods & Pharmaceuticals N.T.M. S.p.A ("Fine Foods"). The agreement grants Fine Foods an exclusive license for the production and supply of five formulations containing OptiBiotix's LPLDL® strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties. ............ OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into license agreement with ALFASIGMA S.p.A. ("ALFASIGMA") to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in Italy. ......... |
Posted at 25/10/2024 08:00 by putinaire Dont you just love how price always seems to edge up for a big dump. It's like factoring share price lol |
Posted at 24/10/2024 09:11 by kreature I did say it was prob just a massive oversight. Easy to do with such a round number I guess….Just got to hand the shares back somehow now I suppose ? Or unsell them? DunnoRNS, ……. OptiBiotix Health plc ("OptiBiotix" or the "Company" or "the Group") Total Voting Rights OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM. |
Posted at 24/10/2024 08:41 by putinaire OPTI RNS recently, included advice to PBX[... OptiBiotix advised of its recent successful fundraise of £1.35m by the Company and identified lack of market communication by Mr Andersen as the main reason for the failed PBX fundraise. OptiBiotix requested that PBX increase its news flow to potentially support the share price and build positive investor sentiment ...] Did they advise SBTX yesterday too? So more could be sold? |
Posted at 20/10/2024 18:56 by kreature Jan 2024 RNS Sweetbottix:SP 28.5p ‘ Given recent progress, the Company's focus has moved on from manufacturing scale up to engaging with commercial partners to launch products. Discussions are ongoing but are likely to involve a phased introduction… Feb 2024: informal chats with significant shareholders ? I think that would allowed before a placing ? I might suggest it March 2024 Placing at 20p Oct 20th share price today 13.14p (minus 52% YTD) |
Posted at 18/10/2024 08:16 by kreature ‘ OptiBiotix requested that PBX increase its news flow to potentially support the share price ’So was the idea to manipulate the share price with news ? What news ? Very confusing RNS. How would Opti know if there were any unreleased news ? |
Posted at 18/10/2024 08:06 by kreature ‘ We firmly believe that Mr A!??!? was pursuing a strategy to suppress the share price’Really well spotted by Opti if true. Seems baseless to me tho. Where’s the proof? |
Posted at 23/7/2024 09:26 by institutional investments Notice how fast opti share price goes up each july?Do you genuinely believe that's a real market? Or a created market for the sells to come? |
Posted at 12/7/2024 11:36 by vlad the impaler OPTI cant really achieve anything on scale eitherTake past revenues (if you believe them). Now the losses. OPTI do not give margins but other similar companies do around the world. Discount on current Manu prices would be negligible on increased scale. It's why opti do not offer scaled margins to investors on the Manu & Distribution costs side We already know their products cant really be repriced then, as that element cant really change much. Plus we can derive sales as none, if play safe and discount geared receivable's. So they have no competitive new edge to introduce for the retail side Selling bulk powders to industry? Again, look globally at those that tried over the past 10 years Where are they now? I think OPTI themselves sum it up re scale, in most financials anyway example sales £320? COS £324 How many decades you all need to see the issue on scaling? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
